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s u m m a r y
Objective: Synovium is increasingly a target of osteoarthritis (OA) treatment, yet its optimal measure-
ment is unclear. Using dynamic contrast enhanced (DCE) MRI in knee OA patients before and after
intraarticular steroid injection, we compared the responsiveness of static synovial volume measures to
measures of dynamic changes in synovial enhancement, changes that are strongly related to synovial
vascularity.
Methods: Ninety three patients underwent DCE-MRI before and 1e2 weeks after intra-articular injection
of 80 mg methylprednisolone. Synovium was segmented and volume, relative enhancement rate (RER),
maximum relative enhancement (REmax), late relative enhancement (RElate) and pharmacokinetic pa-
rameters (Ktrans, ve) were calculated. KOOS (knee injury and osteoarthritis outcome score) pain score was
recorded before and after injection. Standardized change scores were calculated for each parameter.
Linear regression and Pearson's correlations were used to investigate the relationship between change in
MRI parameters and change in pain.
Results: The change in standardized score for the measures of synovial enhancement, RElate and REmax
were 0.58 (95% CI 0.79 to 0.37) and 0.62 (95% CI 0.83 to 0.41) respectively, whereas the score
for synovial volume was 0.30 (0.52 to 0.09). Further, change in knee pain correlated more strongly
with changes in enhancement (for both REmax and RElate, r ¼ 0.27 (95% CI 0.45 to 0.07)) than with
changes in synovial volume 0.15 (0.35 to 0.05).
Conclusion: This study suggests DCE-MRI derived measures of synovial enhancement may be more
sensitive to the response to treatment and more strongly associated with changes in pain than synovial
volume and may be better outcomes for assessment of structural effects of treatment in OA.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
Synovitis is a common finding in the knees of patients with
painful osteoarthritis (OA). Pain decreases after intra-articular
steroid treatment and this may be related to effects on the syno-
vium1. MRI is well suited to assessing synovial changes and by using
intravenous contrast agent to differentiate synovial fluid from
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enhancing synovitis, the volume of enhancing synovitis can be
measured.
In knee OA, the synovial volume has been found to be related to
macroscopic thickening, proliferation and vascularization of the
synovium2. Synovial biopsies show that volume is correlated with
inflammatory cell sub-synovial lining infiltration, vascular
congestion, proliferation of lining cells, fibrosis of synovial tissue
and fibrin deposition on the synovial surface3. This would suggest
that synovial volume in OA should shrink when the knee is treated
with a potent anti-inflammatory such as intra-articular steroids
and that change in synovial volume might be a good outcome
measure for studies of anti-inflammatory treatments of OA. We
recently demonstrated4 that synovial volume shrinks modestly
after an intraarticular steroid injection but that the change in vol-
ume explained only around 3% of the reduction in knee pain
experienced. Dynamic contrast enhanced (DCE) MRI, where images
are acquired every few seconds after contrast injection, allows
assessment of the time-course of contrast enhancement.
DCE-MRI has been used to study rheumatoid arthritis (RA)5,6,
where the rate and degree of enhancement of the synovium by
contrast has been found to correlatemore strongly with evidence of
inflammation than the synovial volume7e9. DCE-MRI characteris-
tics have been shown to be associated with RA in patients with
early arthritis10. The histological features correlated with contrast
enhancement include infiltration of inflammatory cells into the
sub-synovial layer and especially vascular proliferation. DCE-MRI
has also demonstrated a response to various different treatments
in RA11e14. It has also been used to investigate OA in the hand15
where it has shown a response to treatment in erosive OA of the
interphalangeal joints16.
The aim of this study was to determine whether measures of
synovial enhancement could detect a response to treatment and
how this compared to changes in synovial volume. Structural fea-
tures that are responsive to treatment in OA are being sought and
we hoped that, like in RA, dynamic contrast enhancement might
change more with treatment than synovial volume. An additional
aim of our study was to investigate the relationship between MRI
changes and changes in pain. If dynamic enhancement is more
sensitive to change and better correlated with pain change than
synovial volume, this would suggest that it is a better outcome
measure for OA trials and that change in vascularity is critical to
synovial response with anti-inflammatory treatments.
Patients and methods
Subjects
Men and women aged 40 years and over were recruited from
both primary and secondary care clinics for participation in an open
label study looking at the efficacy of intra-articular steroid therapy
in symptomatic knee OA (ISRCTN: 07329370)17. Subjects were
included if they reported moderate knee pain for more than 48 h in
the previous 2 weeks. Inclusion criteria included imaging confir-
mation of significant OA radiologically defined as Kellgren and
Lawrence grade 2 or greater in any compartment of the knee on
anterioreposterior, skyline or lateral knee radiographs obtained
within the previous 2 years. If X-rays were not available, persons
could be eligible on the basis of findings on MRI scan or at
arthroscopy. MRI and arthroscopy required typical changes of OA
with at least cartilage loss not just fibrillation present. Exclusion
criteria included the presence of secondary OA from gout, previous
septic or inflammatory arthritis, injection with hyaluronic acid or
steroid injection within the previous 3 months, history of knee
surgery within the previous 6 months, concurrent life threatening
illness, any contraindication to MRI scanning, absence of enhancing
synovial tissue on MRI or estimated glomerular filtration rate
(eGFR) less than 44 ml/min. Subjects were provided with an in-
formation sheet about the study and those who agreed to take part
subsequently provided written informed consent. Ethics approval
was received from the Leicestershire Multicentre Research Ethics
Committee.
Screening and baseline assessment
Knee radiography was performed in subjects who had not had a
knee radiograph in the previous 2 years or other imaging evidence
of OA. Those whowere eligible were invited to attend for a baseline
visit. Subjects completed also a series of questionnaires including
the KOOS (knee injury and osteoarthritis outcome score) pain scale
at each time point (the primary symptom outcome). In addition, at
each time point, we asked participants to identify the activity that
caused the most knee pain and to score their current pain with this
activity using a 0e10 visual analog scale (a secondary outcome).
Intervention
Following the MRI scan, arthrocentesis was performed using an
18G needle carried out by one of two experienced clinicians (TON/
NM)usingamedial approach to theknee joint.Using the sameneedle
the kneewas then injectedwith 80mgmethylprednisolone (without
local anesthetic). Synovial fluid obtained was forwarded for analysis
and any subject in whom the synovial fluid white cell count was
found to be greater than 1500/mm3 was subsequently withdrawn
from the study because of concern that they may not have OA.
MRI scan
Contrast enhanced MRI of the knee was performed just before
intra-articular corticosteroid injection and then as close as possible
to 10 days afterward as possible, a time frame corresponding to the
time of maximal response to intraarticular steroids18. We studied
one knee per person (the more symptomatic knee). Contrast agent
administered intravenously using a power injector was
Gadolinium-DOTA (Dotarem®, Guerbet, Paris, France) at a dose of
0.2 ml/kg.
Imaging was performed using a 3T Philips MRI scanner with a
knee coil, unless the knee was too large for the knee coil when a
FLEX-L coil was used instead. A sagittal pre-contrast 3-dimensional
WATSc image was acquired (TR 20 ms, echo time (TE) 4.7 ms, field
of view (FoV) 15 cm  15 cm, 90 slices at a thickness of 1.5 mm, flip
angle 15, matrix size 272  272, pixel bandwidth 433 Hz). The
standard dynamic dataset was acquired using a 3D fast field echo
(FFE) sequence (TR 5.3 ms, TE ~1.5 ms, FoV 14 cm  14 cm, 20 slices
at a thickness of 3 mm, flip angle 30, matrix size 256  228, pixel
bandwidth 543 Hz), (standard sequence). Eighteen 3D images were
acquired at intervals of approximately 22 s. Intravenous contrast
agent was administered between the third and fourth images. Pa-
tients who were too large for the knee coil were imaged using a
modified 3D FFE dynamic sequence (SPGR: TR 9.3 ms, TE ~1.5 ms,
FoV 14 cm  14 cm, 20 slices at a thickness of 3 mm, flip angle 30,
matrix size 256  228, pixel bandwidth 543 Hz) (lower temporal
resolution sequence, LTR). Twelve images were acquired at in-
tervals of approximately 39 s. Contrast agent was administered
intravenously between the second and third images. A post-
contrast T1 weighted fat suppressed turbo spin-echo image was
acquired approximately 10 min after enhancement (TR 550 ms, TE
20 ms, FoV 14 cm  14 cm, 24 slices at a thickness of 3 mm, ETL 3,
matrix size 288  229, SPIR fat suppression, pixel bandwidth
~240 Hz).
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One hundred and twenty subjects had pre and post injection
contrast enhanced images, data on synovial tissue volume (STV)
were available for 111 at baseline and follow-up. In nine subjects no
post-contrast sagittal image was taken or the quality of the image
was considered to be poor, precluding comparison. Of these 111
patients, eleven knees were excluded due to incomplete or inade-
quate images, for example due to subject movement or failure to
tolerate the examination, and a further seven did not show
enhancing synovitis.
Image analysis: segmentation
Synovial volume was measured on the high resolution post-
contrast images (see Fig. 1). Manual segmentation of the synovial
tissue layer was performed on these sagittal post-contrast knee
images by a single observer (interobserver ICC ¼ 0.94), who
assessed baseline and follow-up visit MR images paired, but blin-
ded to order. Data on synovial volume in this study have been
published including a description of our method of segmenting
synovium to yield measures of synovial volume4.
Image analysis: dynamic parameters
For each set of dynamic images, we calculated five parameters at
each voxel of the image as follows:
Two parameters were calculated using the standard extended
Tofts model19 with a population arterial input function (AIF)
calculated by averaging values at each time point in the popliteal
artery over all the patients in the study for whom this could be
measured.
(a) Ktrans (volume transfer coefficient)
(b) ve (fractional extra-cellular extra-vascular space)
Three parameters were calculated directly from the enhance-
ment curve (see Fig. 2)
(c) the maximum relative enhancement rate (RER), which is
defined as the maximum slope of the enhancement curve
relative to the initial intensity.
(d) the maximum relative enhancement (REmax) defined as the
maximum point of the enhancement curve relative to the
initial intensity
(e) the late relative enhancement (RElate) ¼ (Snþ…þSn3)/(4*S0)
defined as the average of the last four points of the
enhancement curve relative to the initial intensity
For each of these five parameter images, the manually
segmented regions of synoviumwere overlayed onto the parameter
images, via image registration, and the median value across all the
voxels within these regions was calculated.
Statistical analysis
The mean difference between the baseline and follow-up visit
in MRI parameters plus the KOOS pain subscale, was calculated
with 95% confidence intervals. This allowed assessment of the
degree of change in each of the parameters at follow-up in the
original units of measurement. To allow comparison of the
Fig. 1. (a) Sagittal post contrast T1-weighted fat suppressed turbo spin-echo image after intravenous contrast enhancement with the synovial segmentation ROI outlined in green.
Manual segmentation of the synovial tissue was performed on the sagittal post-contrast T1W FS image by a single observer. Segmentations were carried out paired, blinded to order.
Using computer image analysis, cartilage was excluded by thresholding using the sagittal pre-contrast scan and the synovial fluid using the sagittal post-contrast scan (see also
Ref. 4) The synovial volume is shown in Table II. (b) axial image from the DCE MRI sequence showing the placement of the ROI outlined in green. The ROI was determined from the
pre and post contrast sagittal images and was then transferred to the axial dynamic dataset (truncated by the field-of-view of the dynamic images) for the DCE-MRI analysis.
Fig. 2. A typical time series Si(t) showing the values used to calculate parameters RER,
RElate, and REmax.
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magnitude of change across the parameters which used different
scales of measurement, each parameter was firstly converted to a
standard score (z-score). We then formed one ‘score’ variable with
each parameter having a value at each time point. (Ktrans to KOOS
pain); each parameter was separated through the creation of
additional dummy variables (collectively the ‘parameter type’).
We then used random-effects multiple linear panel regression to
assess the degree of change in each variable at follow-up, in terms
of these z-scores. The model can be expressed formally as
yit ¼ Xit1bþ Xit2bþWi þ Uit , where i ¼ participant ID as the panel
(random-effects) variable, linking observations from the same
participant, and t ¼ the study visit (coded as either 0 for baseline,
and 1 for follow-up visit) yit ¼ standard score variable,
Xit1 ¼ parameter type (coded as a set of five dummy variables),
Xit2 ¼ parameter type-by-study visit interaction effect (which al-
lows for the standardized change to differ between the parame-
ters), Wi ¼ subject-specific random effect (which we assume is
randomly distributed, and uncorrelated with the predictor vari-
ables), and Uit ¼ error (which we also assume is randomly
distributed). The unit of analysis for this model was therefore the
patient. Using this method allows construction of 95% confidence
intervals around the standardized change, unlike a more tradi-
tional standardized response mean.
Bivariate linear regression was additionally used to quantify the
magnitude of relationships between the change in each of the MR
measurements (dynamic parameters and synovial volume) and
change in the KOOS pain subscale. For each of the six MR mea-
surements, we carried out a bivariate linear regression model, with
within-subject change in the KOOS pain subscale between baseline
and follow-up as the outcome. The predictor variable in eachmodel
was the within-subject change in one of the six parameters at
follow-up (e.g., change in RER). To examine the strength of corre-
lation of pain change with change in MRI measures, we created
Pearson's correlations (r) between change in the KOOS pain sub-
scale and change in the variables of interest, so that we could
compare across MRI measurements which were measured with
different units. We also constructed 95% confidence intervals
around these correlations. Statistical analysis was undertaken using
Stata version 13.1.
Results
We studied 93 patients (45.16% female, mean age 62.52 years,
further characteristics in Table I). Every dynamic and static
parameter showed a mean reduction in response to treatment
between baseline and follow-up, although the mean percent
reductionwas less for synovial volume (15.4%) than for measures of
enhancement such as maximal and late relative enhancement
(24.4% and 24.6% respectively). The standardized score for change
for the measures of synovial enhancement, RElate and REmax
were 0.58 (95% CI 0.79 to 0.37) and 0.62 (95% CI 0.83
to 0.41), whereas for synovial volume it was 0.30 (95% CI 0.52
to 0.09) (see Table II).
Statistically significant associations were observed between
pain change and change in the dynamic parameters RER, RElate,
REmax and Ktrans. However, the association between pain change
and change in synovial volume was not statistically significant (see
Table III). The correlations (r values) of pain change with change in
synovium were greater for measures of late and maximal relative
enhancement than for synovial volume.
Discussion
The results of this study suggest changes in signal intensity
measurements from synovial enhancement after intravenous
contrast agent correlate with changes in pain after intra-articular
steroid injection. The correlation was stronger than that observed
between volume change and pain change. In the current study only
the RER, maximum and late relative enhancement (REmax and
RElate) and Ktrans change showed a significant association with pain
change.
This study suggests that contrast enhanced intensity measures
such as REmax and RElate may be more responsive than volume
measurements for monitoring synovial change (Table II) and
Table I
Description of persons in study at baseline (unless otherwise stated)
Variable Value N
Age at baseline visit (years), mean (SD) 62.52 (10.69) 93
Females, frequency (%) 42 (45.16%) 93
KellgreneLawrence (KeL) Score e 82y
- Grade 2, frequency (%) 29 (35.37)
- Grade 3, frequency (%) 47 (57.32)
- Grade 4, frequency (%) 6 (7.32)
Number of days to follow up appointment, median (IQR) 8 (7e13) 93
Baseline KOOS pain subscale score* (0e100), mean (SD) 46.75 (14.40) 93
* Scoring for KOOS pain subscale is from 100 (no pain) to 0 (extreme pain).
y 11 patients were assessed for eligibility via MRI scan, rather than radiograph, and so had no KeL score.
Table II
Changes and standardized score for change of the parameters assessing the synovium
Variable name Abbreviation Baseline Follow-up Change at follow-up Change in standardized score at follow-up
Mean (SD) Mean (SD) Mean (95% CI) Mean (95% CI)
Synovial tissue volume (mm3) V 9601 (5251) 8119 (4353) 1482 (2137 to 827) 0.30 (0.52 to 0.09)
Relative enhancement rate (min1) RER 0.048 (0.030) 0.032 (0.020) 0.016 (0.021 to 0.011) 0.61 (0.82 to 0.39)
Late relative enhancement RElate 3.10 (1.37) 2.35 (1.12) 0.76 (0.98 to 0.54) 0.58 (0.79 to 0.37)
Maximal relative enhancement REmax 3.51 (1.46) 2.65 (1.17) 0.86 (1.09 to 0.63) 0.62 (0.83 to 0.41)
Extravascular extracellular volume ve 0.31 (0.22) 0.22 (0.23) 0.09 (0.13 to 0.05) 0.39 (0.60 to 0.17)
Volume transfer coefficient (min1) Ktrans 0.045 (0.033) 0.029 (0.028) 0.016 (0.022 to 0.010) 0.51 (0.72 to 0.30)
KOOS pain subscale score e 46.75 (14.40) 69.68 (18.99) 22.93 (18.85e27.01) 1.13 (1.34 to 0.91)*
NB: *The KOOS pain score runs from 100 (no pain) to 0 (extreme pain).
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consequently may be better structural outcome measures for OA
treatments targeting intraarticular inflammatory processes.
Contrast enhancement depends on a number of factors such as
synovial vascularity and the fractional volume of the extravascular,
extracellular space into which the contrast diffuses which may
change relatively acutely19. On the other hand, synovial volume
may include regions of fibrous tissue which might be chronic.
We included subjects with grade 4 (severe) OA as recent work20
has suggested that they too show structural disease progression
over time and that the synovitis and its severity are correlated with
Kellgren and Lawrence disease grade21.
Although we found a stronger association of synovial signal
intensity changes with pain than synovial volume with pain, this
association was not strong. This compares with a previous 2.5 year
observational study of 270 patients which showed a correlation of
pain with synovitis change using unenhanced MRI of r ¼ 0.21. A
previous cross-sectional study of 95 patients showed a significant
correlation between DCE-MRI and pain (r ¼ 0.4)22. There are likely
to be many other factors apart from synovitis which influence pain
such as bone marrow lesions, psychological issues, reduction in
capsular stretching and others.
One reason why REmax and RElate correlated better than other
measurements of contrast enhancement may be that they are
relatively straightforward to measure and robust, in part because
they do not require high temporal resolution. A previous study
comparing OA and PsA in the hand also found late enhancement
helpful15, although many studies have favored early enhancement
rates7,8,11.
REmax and RElate behaved similarly in this study. That may reflect
the enhancement curve characteristics (Fig. 2) which showed an
increase then slow plateauing of signal intensity over the mea-
surement period making REmax and RElate similar.
Ameasurement similar to RElate could be obtained simply from a
pre-contrast and a single delayed post-contrast image without
requiring a rapid, dynamic imaging sequence. By reducing de-
mands for temporal resolution, this would allow spatial resolution
and coverage to be improved.
There have been a number of studies of treatment response in
RA which have used measures of enhancement rate, maximum
enhancement and/or delayed/static enhancement. The results
have been mixed with the majority of studies demonstrating that
measures of enhancement rate (this is similar to RER in the
current study) and maximum enhancement23e26 yielded similar
trends. In most, stronger results were obtained from enhance-
ment rates23e25,27,28, although in one, the maximum enhance-
ment was more significant29. This may reflect the good
correlation between enhancement rate and histology in RA7,8,30.
The situation is further complicated by differences in definitions
and temporal resolution. In OA, the situation may be different
with lower rates of enhancement, particularly in the early
enhancement phase31.
The use of intravenous contrast agent for accurately assessing
synovitis is widely advocated, even though simple volume mea-
surements are often made. The results of this study suggest that if
intravenous contrast agent is being administered, signal intensity
measurements may be more informative than synovial volume as
they are more sensitive to change and correlate better with
symptoms.
The study has a number of limitations. The low temporal
resolution of the DCE-MRI sequence (22s and in some cases 39s)
limits the accuracy of the model, particularly for estimating
Ktrans. The field of view was also limited reflecting the compro-
mise in DCE-MRI between temporal resolution, spatial resolution
and field of view in the phase encode directions; these could be
improved for measurement of late enhancement where high
temporal resolution is less important. Also, a small subgroup of
patients (16/93) was imaged using a different coil and different
parameters due to large knee size. The differences in MRI repe-
tition time (TR) are unlikely to have a significant effect on rela-
tive enhancement due to the strong T1 weighting of both
sequences used. Furthermore, we have performed additional
analyses which test for whether the magnitude of relationships
differs between sequences, and found no significant differences
between the sequence types (data not presented). Results from
only those patients who had the standard imaging protocol (77/
93) were similar. In addition, the joints were aspirated prior to
injection. Aspiration may have resulted in apparent changes in
measurements for both synovitis volume and enhancement due
to alterations in partial volume effects. However, the reduction in
both synovial volume and enhancement measurements in the
time after aspiration and steroid injection suggests this was not
the dominant effect. In addition, we assessed the correlation of
pain change with synovitis change only in those with synovitis
and by excluding seven patients without quantifiable synovitis,
we may have overstated the association of pain change with
synovitis change in all persons with knee OA. Further, in very
large persons dynamic image sampling was less frequent and we
could have missed a correlation of dynamic change with pain
change.
Among possible other limitations include the multicollinearity
of MRI parameters. Many of the dynamic parameters were strongly
correlated (e.g., rs ¼ 0.98, between REmax and RElate); therefore,
while the results suggesting the superiority of dynamic vs static
parameters are likely to be robust, our ability to distinguish the
relative sensitivity of different dynamic parameters is limited. The
time period between contrast injection and the acquisition of the
post contrast static image used for segmentation limits the accu-
racy of the synovitis segmentation as contrast agent may have
reached the synovial fluid32. The reproducibility of the different
methods has not been assessed. Movement between dynamic im-
ages may degrade reproducibility of measurements such as RER.
This could be reduced by use of image registration33. Other
Table III
Relation of change in pain with change in synovial parameters
Bivariate linear regression of change in [variable, below]
with KOOS Pain subscale score*
b coefficient (95% CI) P r (95% CI)
Synovial tissue volume (cm3) V 0.94 (2.22 to 0.34) 0.15 0.15 (0.35 to 0.05)
Relative enhancement rate (min1) RER 217.37 (388.77 to 45.97) 0.01 0.26 (0.44 to 0.05)
Late relative enhancement RElate 5.08 (8.83 to 1.32) 0.01 0.27 (0.45 to 0.07)
Maximal relative enhancement REmax 4.73 (8.27 to 1.19) 0.01 0.27 (0.45 to 0.07)
Extravascular extracellular volume ve 9.96 (29.89 to 9.98) 0.32 0.10 (0.30 to 0.10)
Volume transfer coefficient (min1) Ktrans 151.18 (299.73 to 2.63) 0.05 0.21 (0.39 to 0.00)
* Each of the variables in the table was entered into a bivariate regression against KOOS pain subscale change at follow-up visit, and subsequently, a bivariate Pearson's
correlation. Note that the KOOS pain score runs from 100 (no pain) to 0 (extreme pain) so that a negative r value would signify that a reduction in synovial volume would be
correlated with a reduction in pain. Note that all coefficients are negative. ‘b coefficient’ ¼ unstandardized regression coefficient. ‘r’ ¼ Pearson's correlation coefficient.
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parameters such as the area under the enhancement curve were
not calculated and these may also provide useful information.
While this study could be criticized as an open label and un-
controlled trial, our focus in this analysis was on comparing static
vs dynamic measures and their relation to pain change, issues
which should not be affected by the presence of a control group.
In conclusion, the results of this study suggest signal intensity
based measurements obtained with contrast enhancement may be
more appropriate outcome measures for synovitis in OA as they are
more responsive and correlate better with symptoms than do
measures of synovial volume.
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